Stay updated with breaking news from Olaparib Tablets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DCGI orders withdrawal of AstraZeneca's Olaparib tablets for gBRCA mutation and advanced ovarian cancer due to potential adverse effects. The drug was
The communication stated that the firm presented the clinical evidence for the withdrawal of indication of Olaparib tablets.
Cgi orders withdrawal of cancer drug olaparib for certain treatments
Get latest articles and stories on India at LatestLY. The Drug Controller General of India has asked drug regulators in all states and Union territories to withdraw AstraZeneca's anti-cancer drug Olaparib tablets for treatment in patients who have received three or more prior lines of chemotherapy. India News | DCGI Orders Withdrawal of Cancer Drug Olaparib for Certain Treatments.
India's DCGI orders the withdrawal of Olaparib for specific cancer treatments after reviewing adverse effects and survival data.